ESC-EAS Joint Session
Biomarkers to improve individual cardiovascular risk prediction
-
Imo Hoefer
Imo Hoefer
Utrecht, Netherlands
Imo Hoefer works as Associate Professor at the Laboratory of Clinical Chemistry and Hematology and the Experimental Cardiology Laboratory at the University Medical Center Utrecht. He focuses on improvement of cardiovascular disease diagnosis, prediction and therapy applying big data, biomarkers and translational preclinical models of human disease. Since 2008, he is nucleus member and current past-chair of the ESC Working Group on Atherosclerosis and Vascular Biology and member of the ESC Council on Basic Cardiovascular Science.
- Ulrich Laufs
Hematological parameters as predictors of mortality, events and complications
Imo Hoefer, Utrecht, Netherlands
Imo Hoefer
Utrecht, Netherlands
Imo Hoefer works as Associate Professor at the Laboratory of Clinical Chemistry and Hematology and the Experimental Cardiology Laboratory at the University Medical Center Utrecht. He focuses on improvement of cardiovascular disease diagnosis, prediction and therapy applying big data, biomarkers and translational preclinical models of human disease. Since 2008, he is nucleus member and current past-chair of the ESC Working Group on Atherosclerosis and Vascular Biology and member of the ESC Council on Basic Cardiovascular Science.
Circulating miRNA for cardiovascular death prediction
Tanja Zeller, Hamburg, Germany
Tanja Zeller
Hamburg, Germany
Prof. Dr. Tanja Zeller is Professor for Genomics and Systems Biology and is leading the molecular cardiology research team at the UKE with the particular interest on emerging molecular biomarkers such as non-coding RNAs and translational aspects. She has longstanding experience in biomarker research and is coordinator of the BMBF-funded e:Med symAtrial consortium, PI of the EU BiomarCaRE Project and PI of several Omics and whole genome sequencing projects. Prof. Zeller is speaker of the BMBF e:Med and DZHK OMICS and systems medicine committee. Furthermore, Prof. Dr. Zeller is head of the CCS and HCHS Biobank and the biobanking working group at the DZHK.
Temporal versus one-time biomarker measurements
Lars Lind
Uppsala, Sweden
Lars Lind is Professor of Medicine and the Linnaeus chair of Medicine at Uppsala University. Consultant in Internal Medicine since July 2008, Chief Supervisor for 24 graduated PhD students, more than 600 published original papers in peer reviewed journals. Professor Lind is mainly performing epidemiological research on risk factors and aetiology of different cardiovascular diseases, nowadays including GWAS, epigenetics, proteomics and metabolomics. PI (or co-PI) of the cohort studies PIVUS, POEM, EpiHealth and SCAPIS.
ICCR-EAS Joint Session
Lifestyle markers are key vital signs to optimize management of cardiometabolic risk
-
Marja-Riitta Taskinen
Marja-Riitta Taskinen
Helsinki, Finland
Marja-Riitta Taskinen is Emerita Professor of Medicine at the Cardiovascular Research Group, Heart and Lung Centre, at Helsinki University Central Hospital. Her research team, which focuses on lipoprotein kinetics in health and lipid disorders and the genetics of familial dyslipidemias, is a member of the Research Program Unit, Diabetes & Obesity Research program at the University of Helsinki. Professor Taskinen is the recipient of numerous awards including the Claude Bernard Award (2002), Edwin Bierman Award (2004), Novartis Award (2006), the Grand Award of the Finnish Foundation for Cardiovascular Research (2011), and the Pohjola and Suomi Mutual Medical Award of the Finnish Medical Foundation (2012). She has been a key player in the European Atherosclerosis Society (President, 2006-2008), International Atherosclerosis Society, European Association for the Study of Diabetes, and the International Diabetes Federation.
-
Benoit Arsenault
Benoit Arsenault
Quebec, Canada
Dr Benoit Arsenault is an Assistant Professor at the Department of Medicine at Université Laval and a research scientist at the Québec Heart and Lung Institute in Québec City, Canada. The research of Dr Arsenault’s team focuses on the impact of lifestyle, genetics and pharmacotherapy on lipoprotein metabolism, cardiometabolic risk and cardiovascular diseases such as calcific aortic valve stenosis. He has authored or co-authored more than 80 peer-reviewed scientific manuscripts in major medical, scientific and cardiology journals and now holds a junior scholar award from the Fonds de recherche du Québec: Santé. He has received several distinctions such as the Young Investigator Clinical Science Award of the European Society of Cardiology in 2011.
SSBs: A simple lifestyle marker associated with cardiometabolic health
Benoit Arsenault, Quebec, Canada
Benoit Arsenault
Quebec, Canada
Dr Benoit Arsenault is an Assistant Professor at the Department of Medicine at Université Laval and a research scientist at the Québec Heart and Lung Institute in Québec City, Canada. The research of Dr Arsenault’s team focuses on the impact of lifestyle, genetics and pharmacotherapy on lipoprotein metabolism, cardiometabolic risk and cardiovascular diseases such as calcific aortic valve stenosis. He has authored or co-authored more than 80 peer-reviewed scientific manuscripts in major medical, scientific and cardiology journals and now holds a junior scholar award from the Fonds de recherche du Québec: Santé. He has received several distinctions such as the Young Investigator Clinical Science Award of the European Society of Cardiology in 2011.
Preventing Type 2 Diabetes by lifestyle: an under-recognised/under-used approach in clinical practice
Jaakko Tuomilehto, Kuwait City, Kuwait
Jaakko Tuomilehto
Kuwait City, Kuwait
Professor Emeritus at Helsinki University, Finland is currently working as the Chief Scientific Officer at Dasman Diabetes Institute in Kuwait. His research interests include non-communicable diseases such as diabetes, cardiovascular disease, cancer and dementia.
He has contributed many landmark studies, including the North Karelia Project, WHO MONICA Project, Finnish Diabetes Prevention Study. He has served for ADA, ESC and WHO committees on diabetes and cardiometabolic risk. He has contributed to over 1600 scientific peer-reviewed publications, and is one of the most cited authors in the field of clinical medicine, and molecular biology and genetics worldwide with h-index 155.
Ectopic fat, non-alcoholic fatty liver disease and cardiometabolic health?
Christopher D. Byrne, Southampton, United Kingdom
Christopher D. Byrne
Southampton, United Kingdom
Chris Byrne is Professor of Endocrinology & Metabolism at University of Southampton, UK. He has published > 250 peer reviewed publications and three books, related to metabolic syndrome, obesity and non alcoholic fatty liver disease. In 2012, he was awarded the Dorothy Hodgkin prize by Diabetes UK. He collaborates with colleagues around the globe and has MRC grant support for collaborative research with colleagues in Seoul and Edinburgh. He was the expert diabetologist advisor to the UK National Institute for Care Excellence NAFLD Guidelines and is Principal Investigator within the Southampton National Institute for Health Research Biomedical Research Centre.
